Market Overview

UPDATE: JP Morgan Maintains Integra LifeSciences at Neutral Following Model Update

Related IART
UPDATE: Integra LifeSciences Announces FDA Clearance And Controlled Market Release Of Expandable Interbody System For Spinal Surgery
Integra LifeSciences Introduces Integra Pocket Strip And Integra Shaped Strip DBM Implants
EMCORE Selling Space Solar Business to Veritas Capital (Fox Business)

JP Morgan reiterated its Neutral rating and $43 price target on Integra LifeSciences (NASDAQ: IART).

JP Morgan commented, "For 2013, we continue to expect adjusted EPS of $3.14 (+1.3%) on total revenues of $878.1M (+5.5%). Excluding the impact of the medical device excise tax (~$0.29), earnings growth is projected at 10.7%. By division, we project Neuro growth of 4.0%, Orthopedics growth of 7.4%, and Instruments growth of (3.9%). Longer term, we see Integra as a 5-6% and 10-11% top- and bottom-line grower, respectively. This compares to management's long-term guidance ranges of 5-7% and 9-13%. For 2014, we model adjusted EPS of $3.48 (+11.2%) on total revenues of $925.6M (+5.4%)."

Integra LifeSciences closed at $38.78 on Wednesday.

Latest Ratings for IART

DateFirmActionFromTo
Aug 2014OppenheimerMaintainsOutperform
May 2014OppenheimerMaintainsOutperform
Apr 2014Lake Street CapitalInitiates Coverage onBuy

View More Analyst Ratings for IART
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Reiteration Intraday Update Analyst Ratings

 

Related Articles (IART)

Around the Web, We're Loving...

Get Benzinga's Newsletters